News

November 28, 2017

All-RAS Oncobeam Test von der BARMER erstattet

In einer gemeinsamen Veranstaltung informierten die BARMER, IndivuTest und LADR Der Laborverbund über „Liquid Biopsy: Moderne Tumordiagnostik aus dem Blut“.

Read More

November 23, 2017

The Importance of Tissue Quality for Personalized Medicine

Leading experts of the European Society of Digestive Oncology (ESDO) in the field of gastrointestinal cancer discussed new recommendations for the clinical relevance of molecular diagnostics during the 17th European Society for Medical Oncology (ESMO) world congress on gastrointestinal cancer in Barcelona.

Read More

November 15, 2017

Indivumed to Exhibit at Molecular Med Tri-Con in San Francisco, USA, February 11–16

Molecular Med Tri-Con 2018 is one of the world’s leading international events in the field of drug discovery, development, and diagnostics.

Read More

November 15, 2017

Dual IHC and Quantitative Image Analysis Evaluating Immune Tumor Microenvironments

It was our great pleasure to take part in the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting, held on November 8–12 in National Harbor, USA.

Read More

Press

January 16, 2018

The Salk Institute and Indivumed Partner to Advance Global Cancer Research

Salk and Indivumed have established a strategic partnership to advance research in precision oncology and personalized medicine by utilizing the highest quality molecular and clinical data in cancer

Read More

January 09, 2018

Investment Plan for Europe: EIB grants loan of EUR 40m to Indivumed

The European Investment Bank (EIB) will provide a loan of EUR 40m to Indivumed GmbH, a physician-led, integrated global oncology company providing high-content tumour data and an optimum quality biobank to third parties such as biopharmaceutical companies and research institutes.

Read More

September 19, 2017

Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development

Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.

Read More

August 02, 2017

MedStar Health Collaborates with Indivumed to Advance Precision Oncology Research

MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.

Read More

Videos

Product Information